|Bid||4.15 x 100|
|Ask||6.60 x 500|
|Day's range||6.39 - 6.60|
|52-week range||4.11 - 8.38|
|PE ratio (TTM)||-3.79|
|Earnings date||7 Nov 2017 - 13 Nov 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y target est||8.00|
BOSTON, Oct. 13, 2017-- Keryx Biopharmaceuticals, Inc., a company focused on bringing innovative medicines to people with kidney disease, today announced that three abstracts for Auryxia ® tablets have ...
One in four of the company's shares is currently being shorted, but bears appear to be wrong about this pharma stock.